Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services | News
Search Refinements

Contract Services News

View news from other Pharmaceutical sectors:
121-135 of 2360 results
Quantum Pharmaceutical signs five-year contract extension with AAH Pharmaceuticals
Quantum Pharmaceutical Limited, the largest business unit in Quantum Pharma's Specials division, has signed a new five-year contract extension with AAH Pharmaceuticals Limited ("AAH").
Contract Research & Services > Contract Services > News
Array BioPharma, Asahi Kasei Pharma collaborate for novel pain and inflammation program
Array BioPharma and Asahi Kasei Pharma announced a strategic collaboration to develop and commercialize select Tropomyosin receptor kinase A (TrkA) inhibitors, including Array-invented ARRY-954, for pain, inflammation and other non-cancer indications.
Contract Research & Services > Contract Services > News
Dr. Reddy's acquires ex-Asia rights to Eisai anti-cancer agent E7777
By PBR Staff Writer
Eisai has signed an agreement to transfer the exclusive global development and commercialization rights, excluding Japan and Asia, to its cancer drug candidate E7777 to Dr. Reddy’s Laboratories.
Contract Research & Services > Contract Services > News
Rich Pharmaceuticals extends CRO deal with Theradex to manage clinical sites in US
Rich Pharmaceuticals has extended its agreement with Theradex Systems to manage its clinical sites in the US.
Contract Research & Services > Contract Services > News
OncBioMune signs MOU for JV with Vitel to develop novel cancer vaccine for Mexico and Latin America
OncBioMune Pharmaceuticals has signed a Memorandum of Understanding (MOU) with Vitel Laboratorios for the purpose of establishing a Joint Venture (JV), to be named OncBioMune Mexico, to develop and commercialize OncBioMune’s portfolio of innovative cancer therapies in Mexico and Latin America.
Contract Research & Services > Contract Services > News
Ligand signs OmniAb platform license agreement with ABBA Therapeutics
Ligand Pharmaceuticals has entered into a worldwide license agreement with ABBA Therapeutics AG, a Swiss biotechnology company developing immuno-oncology therapies.
Contract Research & Services > Contract Services > News
Moberg Pharma, Cadila sign deal for late-stage development of BUPI
By PBR Staff Writer
Moberg Pharma and Cadila Pharmaceuticals have signed an agreement for late-stage development and commercialization of BUPI, a novel lozenge formulation of bupivacaine for pain management in oral mucositis patients.
Contract Research & Services > Contract Services > News
Theratechnologies, TaiMed Biologics sign distribution deal for Ibalizumab
Theratechnologies and TaiMed Biologics have announced a 12-year collaboration agreement to market and distribute ibalizumab in the US and in Canada.
Contract Research & Services > Contract Services > News
Kite Pharma, Genentech partner to evaluate KTE-C19 and atezolizumab combination in NHL
By PBR Staff Writer
Kite Pharma is collaborating with Roche's subsidiary Genentech to evaluate two novel immunotherapies for patients with non-Hodgkin lymphoma (NHL).
Contract Research & Services > Contract Services > News
GSK, Miltenyi Biotec forge cell and gene therapy alliance
By PBR Staff Writer
UK pharmaceutical giant GlaxoSmithKline (GSK) and Germany-based Miltenyi Biotec are collaborating on cell and gene therapy.
Contract Research & Services > Contract Services > News
Orexigen agrees to acquire US rights to Contrave obesity pill from Takeda
By PBR Staff Writer
Orexigen Therapeutics has signed an agreement with Takeda Pharmaceutical Company to acquire the US rights to Contrave anti-obesity prescription medicine.
Contract Research & Services > Contract Services > News
SRI International wins National Cancer Institute contract for PREVENT cancer program
SRI International has been awarded a contract of up to $19.8m from the National Cancer Institute (NCI) PREVENT Cancer Preclinical Drug Development Program to support the development of potential cancer preventive agents or vaccines.
Contract Research & Services > Contract Services > News
Bristol-Myers Squibb, LabCentral partner to support biotech startup companies
Bristol-Myers Squibb and LabCentral have partnered in Cambridge, Massachusetts to support biotech startup companies.
Contract Research & Services > Contract Services > News
AstraZeneca to sell Moventig's European marketing rights to ProStrakan
By PBR Staff Writer
AstraZeneca has agreed to sell the European marketing rights for the opioid-induced constipation (OIC) drug Moventig to ProStrakan, a unit of Japanese biopharmaceutical company Kyowa Hakko Kirin.
Contract Research & Services > Contract Services > News
Exelixis, Ipsen partner to develop cabozantinib in regions Outside US, Canada and Japan
Exelixis and Ipsen jointly announced an exclusive licensing agreement for the commercialization and further development of cabozantinib, Exelixis’ lead oncology drug.
Contract Research & Services > Contract Services > News
121-135 of 2360 results